A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Efficacy and Safety of a topical Unani Formulation in the Management of NÄ?r FÄ?rsÄ« (Eczema) - CSUNF

ational Research Institute of Unani Medicine For Skin Disorders0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年3月6日

研究概览

暂无简介。

•1.Participants having the following signs and symptoms of disease: Itching, History of Asthma / hay fever in 1st degree relatives, Visible flexural eczema, Excoriation, Burning sensation, Lichenification, Crusting, Dry skin.
•2. Participants who are able and willing to comply with the protocol and to sign ICF
•3. Chronicity of more than 6 months and less than 2 years

•1.Participants aged Less than 18 years and more than 65 years
•2. Known cases of significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc.
•3. Any other clinical condition that in the opinion of the investigator would compromise the patientâ??s safety or successful participation in the trial.
•4. Pregnancy and Lactation
•5. Known allergy, sensitivity or intolerance to the study drug or any of its ingredients
•6. Participants with active alcohol intake and/or drug abuse
•7. Participants not willing to sign the ICF and to attend treatment schedule regularly.

发起方

ational Research Institute of Unani Medicine For Skin Disorders